Category: ACN Newswire

土耳其安卡拉, 2025年7月29日 - (亚太商讯 via SeaPRwire.com) - GEN制药公司（GENIL.IS）是土耳其领先的专业制药公司，日前宣布其第一阶段临床试验取得积极结果。该试验旨在评估首创且新型的口服线粒体靶向候选药物 SUL-238 在健康老年志愿者中的安全性、耐受性以及药代动力学（PK）表现。研究结果已在2025年阿尔茨海默病协会国际会议（AAIC®）上于多伦多公布。本次第一阶段临床试验为首个人体试验，采用单次口服递增剂量（SAD）设计，随机、双盲、安慰剂对照，共分为三个部分，纳入了共计53名健康老年志愿者。第一部分包括6个剂量组（口服剂量分别为50、100、250、500、1000和2000毫克，n=23）。第二部分中，研究了单剂1000毫克口服剂量在10名健康老年人的药代动力学特征。第二部分B评估了食物的影响，采用随机、单剂2000毫克口服、双处理、双周期交叉设计（n=20）。试验结果显示，50至2000毫克的单次口服剂量 SUL-238 在受试者中均表现出良好的安全性和耐受性，同时具备良好的药代动力学特征，并能较好地渗透至脑脊液（CSF）。这些结果使得 SUL-238 成为治疗包括阿尔茨海默病在内的神经退行性疾病的有前景的临床开发候选药物。未观察到任何不良反应（AEs）限制剂量递增，SUL-238组与安慰剂组的不良事件发生率相当，且所有不良事件均为轻度或中度。平均终末消除半衰期为0.86至3.80小时，达峰时间为0.50至1.39小时。在进食状态下，血浆药物最大浓度（Cmax）和血浆浓度-时间曲线下面积(AUC0-∞) 分别下降了50%和60%。给药后2小时和8小时脑脊液与血浆的浓度比例分别为21.1%（±6.6%）和74.2%（±46.0%）。GEN董事长 Abidin Gülmüş 表示：“这些令人鼓舞的首次人体试验结果为我们带来了极大信心，标志着我们在应对阿尔茨海默病潜在生物机制方面迈出了重要一步。”GEN研发副总裁、医学博士兼博士 Nadir Ulu 补充道：“在本次第一阶段试验中，SUL-238 展现出优异的安全性和药代动力学特征，结合扎实的临床前数据，使其成为未来临床开发的有力候选药物，有望满足包括阿尔茨海默病在内的神经退行性疾病领域亟待解决的临床需求。”关于 SUL-238SUL-238 是一种首创的新型小分子药物，其源自冬眠机制，靶向细胞的“能量工厂”——线粒体。该药物通过激活线粒体复合体 I 和 IV 来支持线粒体的生物能量代谢，并已在神经退行性疾病、心血管疾病、肾脏疾病及衰老的啮齿动物模型中显著改善线粒体功能。SUL-238 能穿越血脑屏障，并已在临床前研究和第一阶段试验中完成了广泛的安全性评估。GEN 获得了 Sulfateq BV 授权，可将 SUL-238 应用于神经退行性疾病的治疗开发。关于 GENGEN 成立于1998年，是土耳其领先的专业制药公司，致力于在多个治疗领域开发创新疗法。GEN 拥有符合 GMP 认证标准的生产设施，生产高质量且具市场竞争力的药品，并通过两个专属研发中心及研发投资推动原创药物开发。关于 SulfateqSulfateq B.V. 是一家位于荷兰的早期生物技术公司，致力于与学术界和工业研究中心开展战略合作，以加速创新药物的开发。该公司开发了一类新型小分子化合物——SUL 系列药物，旨在维持线粒体健康功能。欲了解更多信息:www.genilac.com.trwww.sulfateqbv.com联系信息Bulutay GünesSr. Head of Corporate Brandb.gunes@genilac.comAli KetenciogluInvestor Relations Managera.ketencioglu@genilac.comKees van der GraafSulfateq CEOinfo@sulfateqbv.com Copyright 2025 亚太商讯 via SeaPRwire.com.

SHENZHEN, CHINA, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) (“ZUNVEYL” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.About Product ZUNVEYLZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. With such a mechanism of action, ZUNVEYL is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001[1]. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed[2]. As the second oral therapy approved by FDA for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better gastrointestinal safety profile to improve compliance of Alzheimer’s disease patients and therefore brings clinical benefits. Patent in regard to use of ZUNVEYL has already been granted in China.About Alzheimer’s DiseaseAlzheimer’s disease is a chronic, progressive neurodegenerative disease characterized by progressive decline in memory and other cognitive functions, among which some of the patients will progress to dementia. Dementia is a kind of syndrome with acquired cognitive function impairment as the core symptom, and can lead to the reduction of patients’ daily living, learning, working and social interaction ability. Alzheimer dementia accounts for 50% to 70% of all types of dementia[3,4]. According to the epidemiological study results published in the Lancet Public Health[5], there are about 9.83 million patients with Alzheimer dementia in China, of which 7.93 million are mild-to-moderate[6]. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future.Currently the clinical treatment of Alzheimer’s disease can be categorized as improving cognitive symptoms and decelerating disease progression[7], and AChEI belongs to the former. According to the Research Report on the Diagnosis and Treatment of Alzheimer’s disease Patients in China[8], the high incidence of side effects is one of the major pain points for existing drugs for Alzheimer’s disease, and drug intolerance is one of the challenges in current treatment of Alzheimer’s disease. Tolerability affects therapy adherence, with data showing that 55% of Alzheimer’s disease patients discontinue their medication after one year, mainly due to GI side effects and insomnia. Medication discontinuation can cause risk to patients themselves, and dissatisfaction and burden among patient’s family, physicians, and caregivers[9]. Therefore, Alzheimer’s disease patients still have an urgent need for safer therapies.On 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”) with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL for the treatment of mild-to-moderate dementia of the Alzheimer’s type. In accordance with the Agreement, the Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan and the Middle East region), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years (the “Initial Term”), it may be automatically renewed every five years upon the expiration of the Initial Term unless terminated by notice from either party.Around six months after obtaining the above rights of ZUNVEYL, the Group promptly submitted the NDA in China, demonstrating its efficient allocation of resources and robust capabilities in registration promotion. ZUNVEYL will further diversify the Group’s innovative drug product matrix and enhance the Group’s comprehensive competitiveness. The Product will synergize with the Group’s various central nervous system products including the innovative drug VALTOCO (diazepam nasal spray) and the original brand drug Deanxit (flupentixol and melitracen tablets) on sale and the innovative drug Y-3 for Injection under development in terms of expert network and market resources. Relying on the Group’s successful commercialization experience and compliant and efficient commercialization system, if ZUNVEYL is approved for marketing, it will bring a new drug option for the treatment of cognitive impairment in Chinese Alzheimer’s disease patients, meeting the clinical need for drugs of both efficacy and safety, improving disease diagnosis and treatment practices, thereby benefiting patients. The Product is expected to have a positive impact on the Group’s financial results.Reference:1. Xu, Hong et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology vol. 96,17 (2021): e2220-e2230. doi:10.1212/WNL.00000000000118322. Safety profile of ZUNVEYL as disclosed by Alpha: https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease- 3. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 1): Dementia Classification and Diagnostic Criteria [J]. National Medical Journal of China, 2018, 98 (13): 965-970. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.0034. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 2): Guidelines For Diagnosis and Treatment of Alzheimer's Disease [J]. National Medical Journal of China, 2018,98 (13): 971-977. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.0045. Jia, Longfei et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet. Public health vol. 5,12 (2020): e661-e671. doi:10.1016/S2468-2667(20)30185-76. Yuan, Jing et al. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. 1 Jan. 2021: 807-817.7. Mayo Clinic. 2024. Alzheimer’s Disease: Therapies to Improve Cognitive Symptoms and Decelerate Disease Progression. https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-200481038. Research Report on the Diagnosis and Treatment of Alzheimer’s Disease Patients in China (2020). Alzheimer's Disease Chinese (ADC). https://www.adc.org.cn/index.php/book/chinaadzlxzbg2020/chinaadzlxzbg2020-381.html9. Data on patient discontinuation as disclosed by Alpha: https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease-About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in Southeast Asia and the Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.

- The HKTDC continues to help SMEs seize digital trade opportunities by co-hosting with the ICC DSI a masterclass on technologies such as electronic bills of lading and blockchain. More than 200 SMEs took part.- Prof Frederick Ma, Chairman of the HKTDC, emphasised that Hong Kong is actively developing its digital trade ecosystem, with a focus on innovation, efficiency and international collaboration, to consolidate its competitive advantages. As digital trade becomes more common, the HKTDC will ensure Hong Kong businesses continue to thrive and enhance the city’s role as a leading supply chain hub.- Pamela Mar, Managing Director of ICC DSI, noted that by aligning its finance, trade and logistics sectors with global digital trade standards, Hong Kong can remain competitive and resilient on the world stage and is well-positioned to spearhead Asia’s digital-trade development.- Andy Lam, Deputy Secretary for Commerce and Economic Development of the HKSAR Government, said that the Government is making reference to the Model Law on Electronic Transferable Records and is considering legislative amendments to remove the legal hurdles in the digitalisation of trade documents. The target is to submit the relevant legislative proposal to the Legislative Council next year to help industry develop technical solutions based on their actual needs.HONG KONG, July 28, 2025 - (ACN Newswire via SeaPRwire.com) - Digitalisation is reshaping the global economy, and companies must embrace digital transformation to capitalise on new opportunities. The 2025-26 Budget announced that the Hong Kong Special Administrative Region (HKSAR) Government would make reference to the Model Law on Electronic Transferable Records (MLETR) advocated by the United Nations Commission on International Trade Law (UNCITRAL) and consider legislative amendments to facilitate digitalisation of trade documents. The legislative proposal will be submitted to the Legislative Council next year. The MLETR is a global standard advocated by the UNCITRAL to provide a legal framework for electronic trade documents. Aligning local legislation with standards of the MLETR is a major endeavour in promoting trade digitalisation. In line with these efforts, the Hong Kong Trade Development Council (HKTDC) and the International Chamber of Commerce Digital Standards Initiative (ICC DSI) co-hosted the “Digital Trade Masterclass” at the Hong Kong Convention and Exhibition Centre to examine the MLETR’s potential impact on Hong Kong’s cross-border trade. Industry experts shared practical insights on digital transformation, helping equip businesses with the information they need to enhance their high value-added service capabilities. More than 200 SMEs participated in the event.As an international financial and trading centre and a leading re-export hub, Hong Kong is able to capitalise on its unique advantages to reinforce connectivity, serving as a bridge linking the mainland and global markets. It provides high-standard professional services, robust financial infrastructure and an innovative environment for international trade. The HKTDC works closely with the HKSAR Government to highlight the city’s strength in delivering high value-added services across the trade supply chain.Speaking at the event, Prof Frederick Ma, Chairman of the HKTDC, said that with the changing trade landscape, there was no better time to reinforce Hong Kong’s competitive advantages. “Hong Kong is actively developing its digital trade ecosystem, with a focus on innovation, efficiency and international collaboration, to consolidate its competitive advantages. As digital trade becomes more common, we are committed to making sure Hong Kong businesses continue to thrive. It is also a great opportunity to reinforce our city’s role as a leading supply chain hub. The HKTDC is dedicated to helping businesses leverage innovative technologies to equip businesses to be future-ready. Our Asian Logistics, Maritime and Aviation Conference (ALMAC) examines trends in global trade and supply chains, innovation and digitalisation, while our support programmes, including Transformation Sandbox, help enterprises scale up their capabilities in key areas, including digital transformation and supply chain solutions, to empower SMEs and start-ups to benefit from digital trade.”Pamela Mar, Managing Director of the ICC DSI, believes Hong Kong, as an international trade and logistics hub already aligned with global standards, will lead Asia’s future digital trade development by remaining competitive and resilient amid a shifting global landscape. “Finance, trade and logistics make up over 45 % of Hong Kong’s economy, so accelerating digitalisation in these sectors will have a positive economy-wide impact.”, said Pamela Mar. “Hong Kong is well-positioned to become a leader in this space by aligning global standards and building on its strength as a trusted hub. The adoption of MLETR is a vital step, providing legal certainty for electronic documents like bills of lading, while streamlining processes and enhancing traceability. But legal reform is only the beginning — even greater gains lie in the private sector stepping up its digital transformation, which can be enhanced by Web3 technologies.”Andy Lam, Deputy Secretary for Commerce and Economic Development of the HKSAR Government, said, “The HKSAR Government is committed to fostering an efficient business environment and maintaining the international competitiveness of Hong Kong. Facilitating the digitalisation of trade documents is part of this strategy. We anticipate that the industry would actively provide feedback and allow the Government to formulate a legal framework that is in line with the needs of the industry, on which basis the industry may propose different technical solutions. On the other hand, the Government is also pressing ahead with Phase 3 of the Trade Single Window, which will not only facilitate the industry in their submission of business-to-government trade documents such as import and export declarations, but will also connect with the Hong Kong Monetary Authority (HKMA)'s Commercial Data Interchange (CDI) to facilitate banks in accessing relevant data to process trade financing.”Industry experts discuss challenges in trade digital transformationAccelerating digital transformation across every link of the supply chain introduces unique challenges. At the Masterclass, the conference brought together specialists in digital trade finance, electronic bills of lading, digital freight and logistics, and digital retail supply chain management to share their practical experience and insights working on digital transformation.Kenise Sin, Senior Data Analyst in the Financial Infrastructure Department at the HKMA, explained: “SMEs’ access to trade finance has long been hindered by different pain points in the process. For instance, the heavy reliance on paper-based documents has led to inefficiencies and difficulties in tracking and verifying the transactions.” She added that HKMA aims to formulate a digitalisation roadmap for sea, road and air transportation cargo data by the end of this year, integrating cargo data sources across jurisdictions with the HKMA’s CDI, to enhance data sharing. In the coming two years, the HKMA will also work with the Airport Authority Hong Kong, the Transport and Logistics Bureau as well as pilot banks to leverage cargo data and CDI to improve digital trade finance.Erik Kwok, Head of Technology and Operations at Air8 — which develops a supply chain finance platform for cross-border trade — echoed these concerns: “Many small to medium-sized exporters struggle to secure funding due to inadequate data for credit assessments, hindering their ability to compete globally. These obstacles are compounded by insufficient support for risk management strategies, leaving SMEs vulnerable in a rapidly evolving market.”Another guest speaker, Candy Chan, Product Manager at IQAX, outlined how digitalising bills of lading can save both time and costs, boosting the efficiency of the entire trade ecosystem. She said many banks, freight forwarders, and customs systems still operate on fragmented digital platforms and lack interoperability. Blockchain, she argued, can bridge these silos: “Each trading partner has unique operational needs when adopting blockchain networks in digital platforms. In cross-border trade, trading and shipping documents are exchanged, and digitalised documents within a blockchain network can solve trust issues within and across networks, backed by MLETR.”Photo download: http://bit.ly/4lNB4t9Prof Frederick Ma, Chairman of the HKTDC attended the Digital Trade Masterclass and delivered the opening remarks on 28 July.(From left) Andy Lam, Deputy Secretary for Commerce and Economic Development, HKSAR Government; Prof Frederick Ma, Chairman of the HKTDC; and Pamela Mar, Managing Director, ICC DSI.Industry experts shared insights and challenges on digital transformation. Picture shows guest speakers from the Digital Trade Masterclass with the officiating guests.(From left) Kenise Sin, Senior Data Analyst, Financial Infrastructure Department, HKMA; Jack Lee, Chief Operating Officer, GS1 Hong Kong; Bertrand Chen, Chief Executive Officer, Global Shipping Business Network; Andy Lam, Deputy Secretary for Commerce and Economic Development, HKSAR Government; Prof Frederick Ma, Chairman of the HKTDC; Pamela Mar, Managing Director, ICC DSI; Ivy Tse, Co-Chief Executive Officer & Co-founder, FreightAmigo; Erik Kwok, Head of Technology and Operations, Air8; and Candy Chan, Product Manager, IQAX.Over 200 SMEs attended the Digital Trade Masterclass, reflecting strong interest.Media enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Johnny TsuiTel: (852) 2584 4395Email: johnny.cy.tsui@hktdc.orgWinnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit:www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI July 28, 2025 - (ACN Newswire via SeaPRwire.com) - 26th July 2025, CITIC Telecom International Holdings Limited (“CITIC Telecom”, SEHK:1883), Asia-Pacific leading multinational Internet-oriented telecommunications enterprise, has joined hands with its subsidiaries including Companhia de Telecomunicações de Macau, S.A.R.L. (“CTM”), CITIC Telecom CPC and China Entercom to exhibit at 2025 WAIC (World AI Conference) for four years in a row.The theme of this year's conference is “Global Solidarity in the AI Era”. In tune with the zeitgeist and guided by CITIC Group’s philosophy, “CITIC, Your Trusted Partner for Going Global and Coming to China”, CITIC Telecom focuses on the strategic direction of “AI+ Connect for Global Reach”. At the WAIC 2025, a compelling display of breakthroughs were showcased, including empowering intelligent business upgrades, enhancing connectivity in digital economies, reinforcing the dual strategies of “Going global” and “Coming to China” market flows, and integrating AI more deeply into real-world industry scenarios.CITIC Telecom continues to play a vital bridging role by actively engaging in the global technology ecosystem enabling Chinese enterprises to pursue “Going Global” strategies while accelerating international enterprises in “Coming to China”, fueling the growth of intelligent technologies.Smart CITIC: Creating Possibilities TogetherCITIC Group participated prominently in this year’s WAIC under the theme “Smart CITIC: Creating Possibilities Together”. Leveraging its integrated strengths in “Technology, Industry & Finance”, the Group showcased a wide range of innovative AI applications and industry-specific AI solutions across technological innovations, emerging industries, financial empowerment, and internationalization. As a key component and strategic pillar of CITIC’s new consumption segment, CITIC Telecom significantly contributed to the “Technology Innovation” and “Internationalization” zones. With close collaboration among its subsidiaries, the exhibit demonstrated its robust foundational tech capabilities, industrial empowerment and ecosystem synergy. It has further unlocked high-quality AI-driven growth, providing CITIC’s intelligence and smart solutions to enhance digitization in China and connect global digital economies. Additionally, a series of on-site “CITIC AI+ Practice Sharing” sessions offered valuable insights into the practical applications and commercial potential of its innovations. “AI+ Connect” for Global Reach: Powering the Next Engine of High-Quality DevelopmentAmidst rapid global digital growth, CITIC Telecom, an important cornerstone of CITIC Group’s international business, is actively embracing China’s “AI+” and high-standard opening-up strategies. It also focuses on fostering a globally interconnected digital ecosystem, deepening the two-way pathways for “Going global” and “Coming to China”, and contributing to a more open, trusted, and mutually beneficial global digital landscape.To realize this strategic vision, CITIC Telecom has established a robust global presence across five continents, comprising nearly 170 Points of Presence, 21 Cloud Service Centers, over 30 Data Centers, and three 24x7 Security Operations Centers (SOCs). These resources and infrastructure support highly responsive, global coverage, agile, digital and intelligent cloud-network-security services. Therefore, it not only provides cybersecurity protection and intelligent connectivity for both central state-owned enterprises and Chinese enterprises going global, but also delivers fast and reliable localized services to multinational corporations, positioning CITIC Telecom as a vital bridge connecting global and local markets, industries and technologies.To further its localization strategy and capability, CITIC Telecom has enhanced regional collaboration through its subsidiaries. ACCLIVIS, operating extensively across ASEAN markets, has accelerated AI, cloud security and cybersecurity deployments in critical sectors such as healthcare and manufacturing, which has infused the Southbound Corridor with sustained innovation momentum. In Greater Bay Area, CTM plays a pivotal role in the “Digital Macau” initiative targeting focus on enabling the moderate economic diversification of Macau, promote smart government, smart campus, smart transformation of various fields. Harnessing the convergence of AI and telecom technologies, it has become a powerful digital and intelligent engine driving Macau’s high-quality development.CITIC Telecom has empowered over 3,000 Chinese and international enterprises in their cross-border development, serving more than 40,000 local clients worldwide, including over 200 Fortune Global 500 enterprises. This highlights the leap from vision to execution in its global strategy, forging partnerships to shape an interconnected digital future.Harnessing Technology: Empowering the Future of “AI+ Connect”In constructing a globally interconnected digital ecosystem, CITIC Telecom is fortifying its innovation foundations to support the next-generation digital framework for enterprises. Leveraging its extensive technological expertise and innovative R&D framework, it is exploring key areas such as AI+ Big data, AI+ Networking, and AI+ Large Model applications, continuously launching scalable, deployable solutions.In the field of AI data governance, AI Databank integrates Big Data, AI, Large Language models (LLMs) and generative AI to create a unified data platform that eliminates silos and enables seamless cross-system integration. Its innovative AI data governance technology has gained widespread adoption across industries and earned the Silver Medal at the 50th International Exhibition of Inventions Geneva in 2025, highlighting CITIC Telecom's excellence in AI research and innovation.In the realm of network services, the “AI Roaming Data Acceleration Pack” project significantly enhances global data transmission efficiency and stability for multinational enterprises by optimizing routing paths and network nodes. By integrating cutting-edge intelligent technologies with the GSMA Open Gateway standards, this solution has been successfully implemented in smart tourism across Hong Kong and Macau. Its innovative approach also earned the Third Prize in the “Open Gateway Global Use Case Innovation Challenge”.In the area of smart living, CITIC Telecom featured CTM’s pioneering “Smart City” project and its 10 Gigabit network infrastructure development in Macau. Powered by a dual-engine approach combining F5G-A and 5G-A technologies, CTM has built Macau’s first “10 Gigabit All-Optical Network Smart Neighborhood”, achieving full gigabit network coverage in Macau citywide. It enables a number of intelligent applications and drives the digital transformation of public services and urban governance, as well as exemplifying a sustainable, people-centric model of urban innovation. This “Smart City” project has garnered multiple prestigious awards both domestically and internationally, underscoring its contribution to the vision of “Digital Macau” and aligning with national strategies for technological advancement.With full-lifecycle AI service capabilities, CITIC Telecom is creating a robust innovation chain — from foundational infrastructure to advanced applications — to empower industries in their digital and intelligent transformation. This drives enterprises success in the global market.AI+ Connect: Fortifying Data Security and Compliance for a Trusted Digital WorldTechnology continues to accelerate global expansion for businesses, yet it also brings rising concerns over data protection and regulatory compliance. CITIC Telecom has established a comprehensive data security and compliance system for the AI era, aligning with China’s Data Security Law and Personal Information Protection Law, as well as international regulations such as the EU’s General Data Protection Regulation (GDPR) and ASEAN's Personal Data Protection Act (PDPA). With this forward-looking approach, the company has addressed key challenges such as cross-border data transmission, data protection, and financial risk control, providing end-to-end protection to build a trusted and intelligent digital world.To empower the future with intelligence, CITIC Telecom shared multiple lightweight AI+ applications that integrate the strengths of “Technology, Industry & Finance” during the “CITIC AI+ Practice Sharing” sessions, all tailored to empowering global enterprises.“Intelligent Financial Fraud Shield”: Financial Fraud, particularly in cross-border transactions, has become a pressing concern. CITIC Telecom’s “Intelligent Financial Fraud Shield” introduces multi-layered identity verification and real-time transaction monitoring to combat fraudulent behavior in cross-border transactions, effectively safeguarding assets for financial institutions and end users. This solution demonstrates the company’s innovative leadership in the digital finance area.“AI+ Connect: Cybersecurity Redefined with Precise Analysis”: CITIC Telecom has developed an all-round, multi-layered intelligent cybersecurity framework to enhance cyber defense. To effectively prevent external threats and data breaches, its AI Pentest simulates real-world attacks and scans for vulnerabilities, enabling proactive threat detection and remediation. Supported by three self-deployed, self-managed AI-driven Security Operations Centers (SOCs), the system constructs a robust and resilient defense that integrates machine learning, big data analytics and large model technologies for real-time threat monitoring and automated response. Meanwhile, the “AI Guardrail” spans from endpoint to transmission layers, guarding against unauthorized access and cross-border data leaks.“AI+ Connect: From Technology Empowerment to Data Empowerment”: Harnessing patented innovations, CITIC Telecom applies intelligent algorithms and big data analytics to help enterprises streamline data governance, integrate cross-system resources, and automate intelligent analytical reports. These capabilities also support diverse small-scale AI applications leveraging large model technologies, from data collection and monitoring to compliance reporting. Through a unified data platform, the company is reimagining enterprise-grade data governance architecture with cutting-edge technologies.Moving forward, CITIC Telecom remains committed to “Connecting the world” and advancing the “AI+ Connect” for enterprises. By leveraging the CITIC Group’s financial, technological and industrial synergies, the company will continue to deepen its AI investments, accelerating the transformation of applicable, manageable, and reliable technologies into real-world solutions. As global cooperation in the smart era grows, CITIC Telecom strives to be a pivotal bridge connecting China and the world, facilitating high-standard opening-up strategies and supporting Chinese enterprises expand globally.Visit Our Booth at H2-A308In this era of digital intelligence, technological innovation stands as the core driver of enterprise resilience and national progress. Embracing this spirit, CITIC Telecom is fast-tracking its technological roadmap to expand its global “Tech+” presence by integrating AI, big data, cloud computing and cybersecurity. We look forward to partnering with industry peers to ignite the future of intelligence and shape a world of shared success.For more details on “CITIC AI+ Practice Sharing”, please visit: https://mp.weixin.qq.com/s/svkprkpnnoC04gdsKZh9HAAbout CITIC Telecom International Holdings Limited (HKEx: 1883)CITIC Telecom International Holdings Limited was established in 1997 in Hong Kong, and was listed on the Hong Kong Stock Exchange on 3 April 2007. As one of the largest international telecommunications hubs in Asia Pacific, CITIC Telecom provides full-scale international telecommunications services to carrier clients around the globe, and integrated enterprise services in Southeast Asia through its wholly-owned subsidiary Acclivis Technologies and Solutions Pte. Ltd.CITIC Telecom International CPC Limited (“CPC”), CITIC Telecom’s wholly-owned subsidiary, provides end-to-end information and communications technology solutions to multinational corporate clients and business clients. CPC is one of the most trusted partners of these clients in the Asia-Pacific region, and provides a full range of ICT services to major enterprises and multinational corporate clients in Chinese mainland through its subsidiary China Enterprise ICT Solutions Limited.CITIC Telecom holds 99% equity interest in Companhia de Telecomunicações de Macau, S.A.R.L. (“CTM”). CTM is one of the leading integrated telecommunications services providers in Macau, and is the only full telecommunications services and ICT services provider in Macau. With a leading position in the market, CTM plays an important role in the ongoing development of Macau. CITIC Telecom has established branch organisations in 22 countries and regions, with approximately 2,500 staff and nearly 170 PoPs, and business serving 160 countries and regions, connecting to over 600 operators globally, and serving around 3,000 multinational corporations and 40,000 local companies around the globe.CITIC Group Corporation, a large multinational conglomerate headquartered in the People’s Republic of China, is the ultimate holding company of CITIC Telecom.For more information, please visit: www.citictel.comMedia Enquiry:CITIC TelecomMs. Sylvia LiTel: +852 3423 3168Email: sylviali@citictel.comCatherine YuenCITIC Telecom CPC (852) 2170 7536Email: catherine.yuen@citictel-cpc.com Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年7月28日 - (亚太商讯 via SeaPRwire.com) - 品创控股有限公司（"品创控股"或"公司"，连同其附属公司统称为"集团"；股份代号：8066）公布向集团两家全资附属公司山西动创数娱科技集团有限公司（"山西动创"）及赛博幻境（香港）有限公司（"赛博幻境"）的10名合资格雇员（"承授人"）授出购股权，以奖励雇员在推动集团业务持续增长及实现卓越业绩的重大贡献。同时，透过授予购股权，能进一步将雇员的利益与集团的长远发展目标紧密结合，激励雇员积极参与集团的未来发展，提升整体竞争力及经营表现，并巩固雇员长期为集团服务的承诺及意愿。购股权计划合共授出52,500,000份购股权，每份购股权赋予承授人权利认购一股股份，行使期为授出日起计十年。值得一提的是，是次授出之购股权的行使条件与山西动创及赛博幻境的业绩挂钩，两家公司截至2025年9月30日止九个月的未经审核税前溢利总额需不少于7,500万港元，此举反映集团对两家附属公司未来表现及业绩达目标高度信心。关于品创控股有限公司品创控股有限公司的使命是妥善运用公司所获得的资本与独特投资机会，为股东提供稳定的优渥收入与获利。品创由三个主要事业部门组成，包括智能卡制造服务、投资服务与资源回收投资，主要业务为生产及销售智能卡、提供定制智能卡应用系统、提供财务及管理咨询服务、废旧金属销售及贸易、以及媒体与娱乐行业之投资。公司的总部位于香港，旗下控股公司与投资则遍布大中华地区。关于山西动创数娱科技集团有限公司山西动创数娱科技集团有限公司（前称"海南动创数娱科技集团有限公司"）从事运营泛娱乐数字生态系统会员电子商务平台，平台主要提供带私域流量的娱乐电子商务，包括提供数字产品及服务。关于赛博幻境（香港）有限公司赛博幻境（香港）有限公司（前称"智能生产管理系统有限公司"）从事提供人工智能语音服务。 Copyright 2025 亚太商讯 via SeaPRwire.com.

上海，2025年7月28日 - (亚太商讯 via SeaPRwire.com) - 2025年7月26日，中信国际电讯集团有限公司（股份代号：1883）携旗下澳门电讯（CTM）、中信国际电讯CPC、中企通信等多家子公司，连续第四年在中信集团的统一部署下亮相2025世界人工智能大会。中信国际电讯紧扣本届大会"智能时代 同球共济"主题，以中信集团"要出国、找中信，来中国、找中信"服务品牌为引领，聚焦"智链国际 服务全球"战略方向，全面展示在人工智能技术与大模型发展领域的前沿探索，呈现在推动企业智能化升级、加速数字经济互联互通、强化企业"走出去"与"引进来"双循环支撑体系、以及推动AI技术与产业场景深度融合等多方面的创新实践与突破性成果。中信国际电讯正持续发挥桥梁纽带作用，深度参与全球科技生态建设，助力企业"走出去"、"引进来"，为全球智能科技发展注入新动能。"智慧中信 共创新可能"本届大会，中信集团以"智慧中信 共创新可能"为主题重磅亮相，依托"科技-产业-金融"循环联动的综合优势，集中呈现了在科技创新、新兴产业、金融赋能及国际化等领域的AI前沿应用与行业解决方案。作为中信集团新消费板块的关键组成部分，中信国际电讯重点参与了集团展区"科技创新"与"国际化"两大主题区域的展示，充分发挥旗下子公司协同优势，强化技术底座支撑、产业赋能和生态协同，全力释放 AI 高质量发展动能，为数字中国建设及全球数字经济互联互通贡献中信智慧和中信方案。与此同时，中信国际电讯还在展区现场开展多场「中信AI+实践分享」互动演示，向业界生动呈现这些创新成果的实践价值与应用潜力。 "智链"国际，服务全球，燃动高质量发展"新引擎"全球数字经济迅猛发展，中信国际电讯作为中信集团国际化业务的重要支撑力量，积极践行国家"人工智能+"与高水平对外开放战略部署，致力构建全球互联的数智生态体系，持续拓展"走出去""引进来"双向通道，打造开放、互信、共赢的全球数字生态。为实现这一战略目标，中信国际电讯已在全球五大洲部署了丰富资源，近170个网络服务节点、21座云平台、30+数据中心及3座全天候运营的安全运营中心（SOCs），构建起全球范围内覆盖广泛、响应敏捷的数智云网安服务。不仅"智链"央国企及中资企业的全球安全连接需求，并为众多外资跨国机构提供敏捷可靠的本地化智能云网安服务，成为连接国际与本土、产业与科技的关键桥梁。此外，中信国际电讯也进一步深化区域协同与属地化运营能力。旗下子公司ACCLIVIS深耕东盟市场，积极推动AI、云网安全等技术在医疗、制造等领域应用，为南向通道注入源源不断的创新动能；在港澳及大湾区，澳门电讯（CTM）深度参与"智慧澳门"建设，聚焦助力澳门经济适度多元发展，推动智慧政务、智慧校园、智慧转型等领域，成功打造出AI+通信技术融合的区域协同项目，为区域高质量发展提供强有力的数智支撑。截至目前，中信国际电讯已累计赋能3000余家中外企业跨境发展，服务全球超过4万家本地客户，其中包括200余家世界500强企业，切实将"全球战略"规划图转化为实景图，携手合作伙伴，共筑智能互联的数字未来。科技引领，聚势赋能，"智链"未来新篇章中信国际电讯不断夯实技术创新根基，打造面向未来的企业级数字能力底座，构建全球互联数字新生态。公司凭借深厚的技术积累与创新研发体系，围绕AI+大数据、AI+网络、AI+大模型应用等核心方向，持续推出可规模化复制的落地方案。在AI数据治理领域，"AI Databank智数库"数据智能平台深度融合大数据、AI、大语言模型（LLM）和生成式AI技术，构建统一数据平台，成功打破数据孤岛，实现多业务系统数据的无缝整合，已在多行业中实现广泛应用。凭借其突破性的人工智能数据治理技术与前瞻的实用价值，AI Databank更是获得了2025年"第50届日内瓦国际发明展览会银奖"，这一国际权威认证彰显了中信国际电讯在AI赛道科研与创新的优秀能力。在网络服务领域，"AI智能加速包"通过优化网络路由和节点，显著提升跨国企业全球数据传输效率和稳定性，结合先进数智技术与GSMA Open Gateway国际标准，已成功应用于港澳智慧旅游场景，获得了"Open Gateway全球应用场景设计开发大赛三等奖"的殊荣。在智赋民生领域，中信国际电讯展示了澳门电讯"智慧城市"方案及万兆网络基建发展。澳门电讯率先以F5G-A与5G-A双擎技术为基座 ，实现千兆网络澳门全域覆盖，并建成澳门首个"万兆小区"，打造更多智能应用场景，推动公共服务和城市管理的数字化转型，塑造"科技以人为本"的可持续未来。项目斩获多个国内国际一流奖项，彰显"数字澳门"与"科技强国"的同频共振。凭借AI技术的全生命周期服务能力，中信国际电讯正在逐步建立起从底层基础设施到上层应用的完整创新链条，为产业的数智转型提供强有力支撑，助力企业在全球化进程中赢得竞争优势。合规护航，数据强基，"智链"可信数字世界技术创新推动企业迈向全球化新高度，但数据安全与合规风险亦随之凸显。中信国际电讯积极响应国家《数据安全法》、《个人信息保护法》，并对接欧盟GDPR、东南亚PDPA等国际标准，前瞻布局AI时代的数据安全与合规服务体系，重点解决跨境数据传输、信息存取保障及金融风控等关键挑战，为构建"智能可信"的数字世界提供全栈式安全保障。智汇未来，中信国际电讯在「中信AI+实践分享」环节，聚力分享多个融合"科技-产业-金融"三大领域的轻量化AI+应用项目，致力以数智技术服务全球企业。《AI赋能金融防欺诈项目》聚焦金融安全领域。在跨境交易中，金融防欺诈已成为保障交易安全的关键一环。中信国际电讯推出的"AI赋能金融防欺诈解决方案"通过多层次的身份验证与实时交易监控，有效防止跨境交易中的欺诈行为，保障金融机构和用户资产安全，展现数字金融领域创新实力。《智链｜安全重启，精准智析》专注于新一代网络安全防护体系的建设。中信国际电讯构建了全方位、多层次的智能安全防御矩阵，AI Pentest智能渗透测试系统通过模拟攻击与漏洞扫描，实现对潜在安全隐患的主动识别和修复，助力企业有效防范外部威胁与信息泄露风险；配合三个自建、自营、自管的AI-SOC智能安全运营中心，依托机器学习算法和大数据分析能力，整合AI大模型技术，提供实时威胁监测与自动化应对能力，为企业构建强韧的安全屏障；"AI安全围栏"则覆盖从终端到传输层的各关键节点，有效阻断非法访问、跨境数据泄露等安全风险。《智链｜从技术赋能到数据赋能》以数据治理与价值挖掘为核心。中信国际电讯通过创新专利技术、智能算法与大数据分析，协助企业实现安全高效的数据治理、跨系统整合及智能分析报告生成。同时赋能企业快速利用大模型技术，多元化小场景应用，处理数据收集、监测与合规报告。通过统一数据平台，以创新技术重塑企业级数据治理架构。面向未来，中信国际电讯将继续以"链接"为本、以"智链"为要，依托中信集团的金融、科技与产业协同优势，持续加大AI领域投入，推动更多"可用、可管、可信"的技术成果转化落地，在智能时代的全球合作浪潮中，担当中国企业高水平开放与科技出海的重要桥梁。相约H2馆A308展区路漫漫其修远兮，吾将上下而求索。面向数智时代的滚滚浪潮，科技创新是企业应变的核心引擎，更是国家发展的底气。中信国际电讯正加快技术布局，以AI、大数据、云计算、网络安全等为支点，持续拓展"科技+"的全球版图。我们期待与各方同仁携手同行，智启未来，共创共赢。「中信AI+实践分享」详情, 请参阅: https://mp.weixin.qq.com/s/svkprkpnnoC04gdsKZh9HA关于中信国际电讯集团有限公司（股份代号：1883）中信国际电讯集团有限公司于1997年在香港成立，并于2007年4月3日在香港联合交易所上市。中信国际电讯作为亚太最大的国际电讯枢纽之一，为全球运营商客户提供全面的国际电讯服务，并透过全资附属公司Acclivis Technologies and Solutions Pte. Ltd.，在东南亚提供一站式跨区域企业服务。中信国际电讯全资附属公司中信国际电讯（信息技术）有限公司（「CPC」）为全球跨国企业客户和商业客户提供一站式信息及通讯解决方案，CPC是亚太区跨国企业及商业客户最可信赖的主要合作伙伴之一，同时透过附属公司中企网络通信技术有限公司，为中国内地大型企业及跨国商业客户提供全方位ICT服务。中信国际电讯持有澳门电讯有限公司（「澳门电讯」）99%权益。澳门电讯是澳门主要的综合电讯服务供货商之一，亦是澳门唯一提供全面电讯和ICT服务的供应商，具市场领先地位，对澳门的持续发展举足轻重。本集团在全球22个国家和地区设有分支机构，拥有约2,500位员工，全球网络节点近170个、业务覆盖达160个国家和地区，连接世界上600多家运营商，服务3,000多家跨国企业以及4万余家当地企业。中国中信集团有限公司为一家总部设于中国的大型综合性跨国企业集团，是本公司的最终控股公司。如欲索取更多数据，请浏览以下网址：www.citictel.com。新闻垂询：中信国际电讯李凯雯小姐电话：+852 3423 3168电邮：sylviali@citictel.com中信国际电讯CPC / 中企通信黄秀娟小姐电话：+852 2170 7511电邮：micty.wong@citictel-cpc.com Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, July 28, 2025 - (ACN Newswire via SeaPRwire.com) - Phoenitron Holdings Limited (“Phoenitron” or the “Company”, together with its subsidiaries, the “Group”; stock code: 8066) announced the grant of share options to 10 eligible employees (the “Grantees”) of its two wholly-owned subsidiaries, namely Shanxi Dongchuang Digital Entertainment Technology Group Company Limited (“Shanxi Dongchuang”) and CyberMirage (HK) Limited (“CyberMirage”). This initiative recognizes the significant contributions these employees have made in driving the Group’s sustained growth and exceptional performance. The grant of share options also further aligns employees’ interests with the Group’s long-term development goals, motivates them to actively participate in the Group's future growth, enhances overall competitiveness and operational performance, and strengthens their commitment and willingness to serve the Group in the long term.An aggregate of 52,500,000 share options were granted under the share option scheme, and each option entitles the grantee to subscribe for one share. The option exercise period is 10 years commencing from the date of grant. Worthy of notice is the exercise conditions for the share options granted are linked to the performance of Shanxi Dongchuang and CyberMirage. The unaudited aggregate profits before tax of the two companies for the nine months ending 30 September 2025 have to be not less than HK$75 million, reflecting the Group’s strong confidence in the future performance and ability to meet performance targets of the two subsidiaries.About Phoenitron Holdings LimitedThe mission of Phoenitron Holdings Limited is to provide shareholders with an optimum steam of steady income and gains by best leveraging the Company’s access to capital and unique investment opportunities. Phoenitron is comprised of three primary business segments, including smartcard manufacturing services, financial consulting and recycled resources investment. Its principal activities are manufacturing and sale of smart cards, provision of customised smart card application systems, provision of financial and management consultancy services, sale and trading of scrap metals and investment in the media and entertainment industry. Headquartered in Hong Kong, the Company has primary holdings and investment across Greater China. About Shanxi Dongchuang Digital Entertainment Technology Group Company LimitedShanxi Dongchuang Digital Entertainment Technology Group Company Limited (formerly known as “Hainan Dongchuang Digital Entertainment Technology Group Company Limited”) operates a pan-entertainment digital ecosystem membership e-commerce platform, which primarily provides entertainment e-commerce with private domain traffic, including the provision of digital products and services.About CyberMirage (HK) LimitedCyberMirage (HK) Limited (formerly known as "PMIS Limited") provides artificial intelligence voice services. Copyright 2025 ACN Newswire via SeaPRwire.com.

RIYADH, KSA, July 27, 2025 - (ACN Newswire via SeaPRwire.com) - The Saudi Electricity Company (SEC) has achieved a significant milestone in its Environmental, Social, and Governance (ESG) performance, as evaluated by S&P Global. The company scored 65 out of 100, marking a 30% increase compared to its 2024 score, and an 85% improvement over its 2023 rating. This accomplishment highlights SEC's strategic progress and reinforces its position as a regional leader and a benchmark for sustainable excellence in the energy sector. Notably, SEC's score exceeds the global utilities sector average of 39 points by 66%, demonstrating its strong commitment to sustainable development. The rating reflects SEC's comprehensive institutional commitment to sustainability, driven by effective governance frameworks, ambitious strategies, and tangible improvements in environmental and social performance. SEC also showcased proactive disclosure aligned with leading international sustainability reporting standards. This progress further underscores SEC's alignment with Saudi Vision 2030, particularly in advancing sustainable energy, enhancing transparency, strengthening investor confidence, and adopting global ESG best practices. SEC reaffirmed its commitment to continuously improving its ESG performance by deeply embedding sustainability across all operations, positioning itself as a trusted and responsible energy provider both regionally and globally.Contact InformationSaudi Electricity Company (SEC)Media Relations Departmentalkahrabacare@se.com.saUnified Call Center: 920000222 Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年7月25日 - (亚太商讯 via SeaPRwire.com) - 下一代肿瘤免疫疗法的领跑者 - 南京维立志博生物科技股份有限公司(「维立志博」或「公司」，股份代号：9887.HK)，宣布于香港联合交易所有限公司（「香港联交所」）主板上市，股票代号为9887.HK。维立志博此次发售每手买卖单位100股H股，最终发行价为每股35.00港元，处于31.60港元至35.00港元价格区间的上限。基础发行股数为36,862,500股H股（经计及发售量调整权获悉数行使及视乎超额配股权行使与否而定），其中香港发售股份数目为16,027,200股H股（经重新分配后予以调整），国际发售股份数目为20,835,300股H股（经计及发售量调整权获悉数行使、经重新分配后予以调整及视乎超额配股权行使与否而定）。超额配售权方面，超额分配的发售股份数目（经计及发售量调整权获悉数行使）为12,821,700股H股，均来自国际发售。募集资金规模方面，算上绿鞋后总发行规模可达1.89亿美元。融资达1.89亿港元 18A最强基石阵容领跑维立志博此次IPO招股引入基石投资者9席，合共认购约5.42亿港元。基石投资者名单集结多家头部医疗专业基金及长线机构，既有国际知名医疗专业基金OrbiMed、TruMed,也包含国内头部公募基金易方达基金；既包括活跃香港二级市场的创新药投资基金Foresight Funds、Sage Partners，更不乏腾讯、高毅等长线价值的国内头部著名私募基金。此外，还有老股东著名医药专业投资基金正心谷资本和汉康资本的加仓。摩根士丹利、中信证券为本次发行之联席保荐人。根据公司策略，维立志博本次IPO募集所得资金净额的约65.0%拟将用于临床阶段候选药物正在进行及计划进行的临床开发和监管事务；约15.0%将用于推进临床前资产、扩展现有管线并优化技术平台；约10.0%将主要用于提升生产能力，其次用于候选药物获批销售后的商业化；以及约10.0%将用于营运资金及一般企业用途。公司于2012年成立，是一家临床阶段生物科技公司，专注于肿瘤、自身免疫性疾病及其他重大疾病新疗法的发现、开发及商业化。公司已建立多元化的产品组合，包括4款核心及主要产品，各款产品组合均处于全球临床进度领先的候选药物之列（不论于其各自药物类别或针对相同靶点的药物当中）。其中，核心产品LBL-024由公司内部开发，是一款处于注册临床阶段的PD-L1与4-1BB双特异性抗体，其为全球首个已处于注册临床阶段的靶向4-1BB受体的疗法，亦有望成为治疗晚期肺外神经内分泌癌的首款获批药物。维立志博的核心业务模式是自主发现、开发及商业化肿瘤免疫疗法。公司通过重点布局肿瘤免疫2.0（IO 2.0）、T细胞衔接器（TCE）和抗体偶联药物（ADC）三大领域，积极探索多领域组合疗法，在全球肿瘤治疗领域建立了差异化竞争优势。截至目前，维立志博的肿瘤管线共12款产品，分别为3款单克隆抗体、5款双特异性抗体、3款抗体偶联药物(ADC)以及1款双特异性融合蛋白。此外，维立志博还布局针2款自身免疫性疾病，包括1款双特异性融合蛋白及1款三特异性抗体。技术平台持续创新维基 多款核心产品显露行业头部潜质公司采用科学驱动的研发方法，开发了包括LeadsBody™平台（CD3 T-cell engager平台）、X-body™平台（4-1BB engager平台）、Linker-payload(ADC技术平台)在内的专有技术平台。技术平台是公司持续创新的基石，并已通过双特异性抗体组合的临床结果得到验证。LeadsBody™平台为靶向CD3的双特异性抗体的开发提供了坚实的技术支持，通过对TCE分子设计进行多样化修改，可精细调节TCE对CD3及肿瘤相关抗原的亲和力，通过精准的空间位阻分子结构设计，做到只在肿瘤微环境中条件启动，从而有效减少细胞因子风暴风险，降低系统性毒性。通过LeadsBody™平台量身定制的分子定位及空间排列能优化疗效与安全性之间的平衡，减少与毒性相关的治疗中断，延长治疗持续时间，提高患者的生活质量。基于这一平台，维立志博已在更具市场前景的实体瘤治疗领域建立了先发优势，截至目前，已布局6款差异化TCE管线产品，成功建起覆盖血液瘤、实体瘤及自免三大疾病领域的TCE产品矩阵。血液瘤领域- LBL-034：GPRC5D/CD3双特异性抗体，用于治疗多发性骨髓瘤。- LBL-043：LILRB4/CD3双特异性抗体，用于治疗急性髓系白血病及多发性骨髓瘤。实体瘤领域- LBL-033：MUC16/CD3双特异性抗体，用于治疗MUC16高表达的实体瘤，特别是卵巢癌、宫颈癌及子宫内膜癌等妇科癌症。- LBL-054：CDH17/CD3 T-cell engager，在结直肠癌、胃癌、胰腺导管腺癌、神经内分泌癌等广泛适应症中有良好应用前景。- LBL-058：靶向DLL3的TCE双特异性抗体-药物偶联物，全球首创的TCE ADC新品类产品，在DLL3表达阳性的小细胞肺癌、神经内分泌肿瘤治疗中具有良好前景。自免领域- LBL-051：全球首创CD19/BCMA/CD3三特异性抗体，可有效阻断B细胞及浆细胞产生自体抗体，同时有可能持续抑制B细胞过度启动、分化及转化为浆细胞，从而有望透过调节B细胞调节的多个方面实现卓越的治疗效果。目前已与知名生物技术风险投资公司Aditum Bio成立的NewCo达成合作。X-body™平台利用先进的抗体工程技术，以2:2结构创造差异化的双特异性抗体，其首个产品LBL-024开创性地采用PD-L1/4-1BB双特异性抗体设计，独特的分子设计使LBL-024能够做到在肿瘤微环境中条件启动4-1BB的激动剂作用，克服有关4-1BB系统性毒性尤其是肝毒性这一主要障碍，降低全身毒性的风险，成功攻克了4-1BB这个肿瘤免疫明星靶点开发的行业难题，成为全球首个也是唯一一款进入注册临床阶段的4-1BB抗体药。 值得特别指出的是，4-1BB作为激动剂，能够重新启动衰竭的T细胞并大量扩增，因此特别适合治疗PD-1/PD-L1耐药的或无效的所谓冷肿瘤。公司目标为发展成为一家综合性生物技术公司，迄今为止，公司已经建立从早期筛选及发现、临床前研究、临床开发、CMC到中试生产的整个药物开发过程中的所有基本功能。该等综合能力凸显公司在药物开发活动的可扩展性及可复制性，使其能够持续推进候选药物的开发。利用该等各不相同但相互关联的功能之间的协同作用，在短短三年内即实现从靶点选择至提交IND的高效药物开发流程，根据弗若斯特沙利文的资料，此优于行业约5至6年的平均水平。作为自主开发的补充，维立志博亦与第三方合作进行候选药物的临床开发及商业化，以通过对外授权许可、商业化合作或其他战略合作更好地把握市场机遇。随着临床资产接近商业化上市，公司可能会考虑建立具商业规模的生产设施，并透过合作及内部销售团队加强商业化能力。南京维立志博生物科技股份有限公司(「维立志博」或「公司」；股份代号：9887.HK)是一家临床阶段的生物科技公司，公司成立于2012年，致力于创新疗法的发现、开发及商业化，以满足中国及全球在肿瘤、自身免疫性疾病及其他重大疾病方面未获满足的医疗需求。公司作为下一代肿瘤免疫疗法的领跑者，拥有涵盖14款创新候选药物的差异化创新管线，其中6款已成功进入临床阶段，4款主要产品均处于全球临床进度领先的候选药物之列。公司采用科学驱动的研发方法，已成功建立涵盖抗体发现及工程、体内及体外疗效评估以及成药性评估的综合研发能力。公司亦开发了包括LeadsBody™平台（CD3 T-cell engager平台）、X-body™平台（4-1BB engager平台）在内的专有技术平台。技术平台是公司持续创新的基石，并已通过双特异性抗体组合的临床结果得到验证。公司成功建立起了在早期研发、转化医学、临床开发、CMC以及业务拓展方面无缝衔接的自主能力。公司候选药物的创新性质及竞争优势，配合其全球视野、积极主动的策略及高效的临床验证使公司成为备受欢迎的合作伙伴。此新闻稿由博达浩华国际财经传讯集团代表南京维立志博生物科技股份有限公司发布。如有垂询，请联络︰博达浩华国际财经传讯集团冯嘉莉女士(852)31506763kelly.fung@h-advisors.global王佩女士(86)13520068960evie.wang@h-advisors.global Copyright 2025 亚太商讯 via SeaPRwire.com.

香港, 2025年7月26日 - (亚太商讯 via SeaPRwire.com) - 作为香港及亚洲其中一个领先的股票开户优惠比较及实战投资教学媒体平台，https://theinvestmedia.com 今日隆重宣布，其网站已独家更新并推出全面优化的「券商开户优惠」专题页面，同时发布一系列由资深专家团队亲自撰写的「券商开户及平台使用实战教学」。此举旨在通过即时、具体且高度可信赖的信息，赋能广大个人投资者，特别是那些寻求券商开户优惠最佳方案及平台实用操作教学的用户，确保其在瞬息万变的全球金融市场中，能够做出最明智、最有效率的决策。Theinvestmedia.com 核心团队由超过八年金融投资实战经验的资深投资银行家、证券商管理层及注册会计师 (CPA) 组成。团队深知金融信息的专业性与即时性对于投资决策的关键影响。本次针对券商开户教学与独家开户优惠的深度更新，正是团队将丰富经验转化为实际用户价值的体现。独家券商开户优惠，实测与深度教学解析为回应市场对券商开户优惠的高度关注，Theinvestmedia.com 不仅详细罗列了当前市场上所有公开的开户优惠，更独家公开与不同持牌金融券商合作伙伴联手推出的开户优惠（详情请参阅 Theinvestmedia.com 官方网页）。这些开户优惠不仅极具吸引力，团队更在教学指南中深度解析其申领流程、条款细则及如何获得最多开户优惠价值，旨在帮助用户清晰掌握，避免任何潜在困惑。团队的目标是让用户在选择不同顶级券商开户时 (例如 IB开户优惠、富途、老虎、OSL等)，能获得最透明、最全面的开户优惠信息。实战指南：从图解券商开户流程到进阶平台使用教学及策略除了开户优惠比较，本次更新的另一大亮点是一系列经团队实测与验证的券商开户及平台使用实战教学。这些教学指南深入浅出地涵盖：图解最详细的开户流程及技巧： 针对常见开户疑问与操作难点，提供图解步骤与提示 (例如图解IB开户)。不同证券平台功能深度导览： 介绍其多元投资产品（例如美股、港股、日股、外汇、债券、ETF 等）的交易界面介绍与常用功能。 外币兑换汇率比较： 针对美元兑港元、日元兑港元、英镑兑港元、欧元兑港元、加元兑港元、澳元兑港元、人民币兑港元、新加坡币兑港元及其他外币的兑换汇率比较，还有不同货币的出金、入金的实用建议。特定交易工具与策略应用： 分享资深团队在实际操作中如何利用券商平台进行有效的风险管理与策略执行。每一篇指南都经过多源头详尽资料收集，并只引用持牌券商官方报告及多次开户测试等权威数据来源。在发布前，所有内容皆会历经严格的多重团队内部核实及资深合规顾问的专业审阅，确保信息的权威性与百分百准确性。以客为本建立信任：用户反馈与客户服务支持Theinvestmedia.com 坚持以用户为中心，平台的信任度建立在透明与快速响应之上。平台已有多名电子邮件订阅用户并持续增长，其积极的互动与反馈广受用户好评，证明了网站内容的实际价值。Theinvestmedia.com更设有专业客户服务团队，可通过网站或电邮（hello@theinvestmedia.com）为用户提供个性化的疑难解答，确保用户如对券商开户优惠、平台使用攻略或任何教学相关信息有任何疑问，都能在办公时间内获得即时、专业的支持。平台创始团队表示：「我们深信，真正有价值的金融信息必须是实用、即时且可验证的。这次针对券商开户的独家开户优惠与实战教学指南，正是我们践行这一理念的最新成果。我们不仅提供『鱼』，更致力于教导『渔』，赋能每位投资者自信地驾驭全球金融市场。」Theinvestmedia.com 诚挚邀请所有对券商开户优惠、证券平台操作及专业投资知识感兴趣的读者，立即浏览 Theinvestmedia.com，探索这些由金融专家经验淬炼而成的独家资源，开启您的稳健投资学习之路。关于 Theinvestmedia.comTheinvestmedia.com 是一个专注于为个人投资者提供开户优惠比较及专业投资教学信息的线上媒体平台，由一支具备逾八年金融实战经验的专家团队运营。网站内容涵盖美股、港股、日股、外汇、债券、ETF 等多元投资主题，并特别针对开户优惠比较、开户教学及股票账户操作 (例如IB开户优惠) 提供深入教学及解析。Theinvestmedia.com 致力于简化复杂的金融概念，帮助投资者建立坚实的投资知识基础，做出明智的理财决定。所有内容均为实际经验分享及向公众作为教学用途，平台不会提供任何投资建议。媒体及读者查询：Theinvestmedia.com 公关部电子邮件: hello@theinvestmedia.com网址: https://theinvestmedia.comFacebook: https://www.facebook.com/theinvestmediaX.com: https://x.com/theinvestmediaSOURCE: Theinvestmedia Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, July 26, 2025 - (ACN Newswire via SeaPRwire.com) - As one of the leading stock brokerage account opening offers comparison and practical investment education media platform in Hong Kong and Asia, Theinvestmedia.com ( https://theinvestmedia.com ) today proudly announced the exclusive update and launch of its fully optimized "Brokerage Account Opening Offers" special section on its website. It's also releasing a series of "Brokerage Account Opening and Platform Usage Practical Tutorials" personally written by its senior expert team. This initiative aims to empower a wide range of individual investors, especially those seeking the best brokerage account opening offers and practical platform usage tutorials, by providing timely, specific, and highly reliable information, ensuring they can make the smartest and most efficient decisions in the ever-changing global financial markets.Theinvestmedia.com's core team comprises seasoned investment bankers, securities firm management, and Certified Public Accountants (CPAs), boasting over eight years of hands-on financial investment experience. The team deeply understands the critical impact of financial information's professionalism and timeliness on investment decisions. This in-depth update focusing on brokerage account opening tutorials and exclusive offers is a testament to the team's commitment to transforming rich experience into tangible user value.Exclusive Brokerage Account Opening Offers: Real-World Testing and In-Depth Tutorial AnalysisIn response to the market's strong interest in brokerage account opening offers, Theinvestmedia.com not only provides a detailed list of all publicly available offers but also exclusively reveals account opening promotions launched in collaboration with various licensed financial brokerage partners (for details, please refer to Theinvestmedia.com's official website). These offers are not only highly attractive, but the team also provides an in-depth analysis in the tutorials, covering the application process, terms and conditions, and how to maximize the value of these account opening offers. This aims to help users clearly understand the benefits and avoid any potential confusion. The team's goal is to ensure users receive the most transparent and comprehensive information when choosing to open accounts with top-tier brokers (e.g., IBKR account opening offers, Futu, Tiger, OSL, etc.).Practical Guides: From Illustrated Brokerage Account Opening Procedures to Advanced Platform Usage Tutorials and StrategiesBeyond the brokerage account opening offers comparison, another major highlight of this update is a series of brokerage account opening and platform usage practical tutorials, thoroughly tested and verified by the team. These in-depth tutorials cover:Most Detailed Illustrated Account Opening Procedures and Techniques: Providing illustrated steps and tips for common account opening queries and operational challenges (e.g., illustrated IBKR account opening procedures).In-Depth Navigation of Different Securities Platform Functions: Introducing the trading interfaces and frequently used features for diverse investment products (e.g., US stocks, Hong Kong stocks, Japanese stocks, forex, bonds, ETFs, etc.) available on these platforms.Foreign Exchange Rate Comparisons : Offering practical advice on foreign exchange rate comparisons for USD to HKD, Yen to HKD, GBP to HKD, EUR to HKD, CAD to HKD, AUD to HKD, RMB to HKD, SGD to HKD, and other foreign currencies, as well as guidance on deposits and withdrawals in various currencies.Specific Trading Tools and Strategy Application: Sharing how the senior team leverages brokerage platforms for effective risk management and strategy execution for wealth management purpose.Every guide undergoes meticulous data collection from multiple sources, citing only authoritative data from official reports of licensed brokers and multiple account opening tests. Before publication, all content undergoes rigorous multi-team internal verification and professional review by senior compliance advisors, ensuring the authority and 100% accuracy of the information.Building Trust with a Customer-Centric Approach: User Feedback and Customer Service SupportTheinvestmedia.com is committed to being user-centric, with its trustworthiness built on transparency and prompt responsiveness. The platform has a growing number of email subscribers, whose active engagement and positive feedback widely confirm the practical value of the website's content. Theinvestmedia.com also maintains a professional customer service team, accessible via the website or email (hello@theinvestmedia.com), providing personalized assistance. This ensures that users with any questions regarding brokerage account opening offers, platform usage guides, or other tutorial-related information can receive immediate and professional support during business hours.The platform's founding team stated: "We firmly believe that truly valuable financial information must be practical, timely, and verifiable. This exclusive update on brokerage account opening offers and practical tutorials is our latest achievement in upholding this philosophy. We don't just provide 'fish'; we strive to teach 'fishing,' empowering every investor to confidently navigate the global financial markets."Theinvestmedia.com sincerely invites all readers interested in brokerage account opening offers, securities platform operations, and professional investment knowledge to visit Theinvestmedia.com immediately. Explore these exclusive resources, forged from the experience of financial experts, and embark on your journey of confident investment learning.About Theinvestmedia.comTheinvestmedia.com is an online media platform dedicated to providing individual investors with brokerage account opening offer comparisons and professional investment education. It is operated by an expert team with over eight years of hands-on financial investment experience. The website's content covers diverse investment topics, including US stocks, Hong Kong stocks, Japanese stocks, forex, bonds, and ETFs, with a particular focus on account opening offer comparisons, account opening tutorials, and stock account operations (e.g., IB account opening offers), offering in-depth analysis and explanations. Theinvestmedia.com aims to simplify complex financial concepts, helping investors build a solid foundation of investment knowledge and make informed financial decisions. All content is for actual experience sharing and public educational purposes; the platform does not provide any investment advice.Media & Reader Inquiries:Theinvestmedia.com Public Relations DepartmentEmail: hello@theinvestmedia.comWebsite: https://theinvestmedia.comFacebook: https://www.facebook.com/theinvestmediaX.com: https://x.com/theinvestmediaSOURCE: Theinvestmedia Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年7月25日 - (亚太商讯 via SeaPRwire.com) - 亿胜生物科技有限公司（"亿胜生物"或"集团"，股票代码：1061.HK）欣然宣布，集团间接全资附属公司珠海亿胜生物制药有限公司已收到国家药品监督管理局批准于中华人民共和国进行多剂量地夸磷索钠滴眼液（"获批准产品"）注册及商业化。获批准产品是一款含有3%地夸磷索钠（5ml:150mg）的多剂量滴眼液剂型，适用于包括结膜上皮损伤和泪液异常在内的干眼症的治疗。该活性药物成分地夸磷索钠是一种P2Y2受体激动剂，它作用于结膜组织，促进含有水分和分泌性粘蛋白的泪液分泌。它还可促进角膜上皮上膜结合型粘蛋白的表达。通过提升泪液中的脂质含量，它从数量和质量上改善泪液异常，并显示出使眼表状况接近正常、改善干眼症状和角膜上皮损伤的疗效。获批准产品将与集团已获批的不含防腐剂单剂量地夸磷索钠滴眼液一并，为不同类型的中国患者提供更多优质治疗选择。此地夸磷索钠滴眼液的成功获批将进一步丰富集团眼科产品组合，增强集团在眼科领域的市场地位。关于亿胜生物（股票代码﹕1061.HK）亿胜生物是一间专注于研发、生产和销售基因工程药物b-bFGF的生物制药企业，拥有包括贝复舒®、贝复济®、贝复新®在内的六种基因工程药物在中国上市销售。此外，公司还拥有包含一系列不含防腐剂单剂量滴眼液和适丽顺®卵磷脂络合碘胶囊等的多元化产品组合，主要应用于眼科及皮肤科处方药领域的创伤修复及疾病治疗。这些产品在公司于中国的44个区域办事处的支持下，在逾14,000家医院进行营销和销售。依托自身在生长因子和抗体技术领域的研发平台，亿胜生物在多个临床阶段拥有强大的项目管线，涵盖广泛的领域和适应症。 Copyright 2025 亚太商讯 via SeaPRwire.com.

上海，2025年7月25日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀有限公司（HKEX1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布以先旧后新配售22,561,000股，集资约15.725亿港元，发行股份数占现有股本约6.87%, 占经扩大后的总股数约6.43%。云顶新耀、卖方（控股股东康桥资本）与配售代理签订先旧后新方式的配股协议，配售22,561,000股份，每股配售价69.70港元，较于最后交易日（即配售及认购协议日期前一天）在联交所报所报收市价每股77.55港元折让约10.12%，亦较于紧接最后交易日（包括该日）前连续五个交易日在联交所所报平均收市价每股73.35港元折让约4.98%，较于紧接最后交易日（包括该日）前连续三十个交易日在联交所所报成交量加权平均价每股60.01港元溢价16.15 %。所得款项总额预期约为15.725亿港元，而所得款项净额（经扣除所有相关成本及开支，包括佣金及征费）将约为15.534亿港元。云顶新耀预计配售所得款项，其中50 %（约7.767亿港元）用于开发自主全球研发平台及新产品管线；另外40 %（约6.214亿港元）用于推进新产品商业化，包括推出新产品；及10 %（约1.553亿港元）用作营业资金以及一般及行政用途。云顶新耀首席执行官罗永庆表示，"此次配售受到多家国际长线持有基金青睐，获得数倍超额认购，反映了资本市场对云顶新耀商业化能力与创新研发实力的高度认可，也体现出投资者对公司长期发展战略的充分信心。我们将充分利用此次融资所得，加快创新药物和AI+mRNA平台的开发，同时推进现有产品的商业化进程。凭借更为充足的资本基础，我们有信心在商业化拓展与研发创新双线并进，不断为患者与投资者创造更大价值。"公司已构建国际领先的、完全整合且本地化的AI+mRNA平台，重点推进肿瘤和自身免疫疾病领域的产品管线开发，包括通用型现货肿瘤治疗性疫苗EVM14、个体化肿瘤治疗性疫苗EVM16，以及自体生成CAR-T项目。- 云顶新耀自主研发的首款个性化mRNA治疗性肿瘤疫苗EVM16 的IIT研究已在今年3月于北京大学肿瘤医院顺利完成首例患者给药。该临床试验初步数据显示，即使低起始剂量也能激发晚期肿瘤患者特异性T细胞反应，具有良好的免疫原性。- 通用型现货肿瘤治疗性疫苗EVM14注射液的新药临床试验申请（IND）已获中国国家药品监督管理局和美国食品药品监督管理局（FDA）受理，成为公司首个实现"中美双报"的mRNA肿瘤治疗性疫苗。云顶新耀嘉善工厂已于2025年6月9日顺利放行首批GMP临床试验样品，该批样品将用于支持云顶新耀在中美两地开展EVM14的临床试验。- 自体生成CAR-T项目也已在人源化小鼠与非人灵长类（猴）模型中验证有效，具备现货型、无需淋巴耗竭、剂量可控等优势，展现了开发用于肿瘤及自身免疫疾病的潜力。拥有全球权益的新一代共价可逆BTK抑制剂EVER001正开展全球多中心临床研究，主要用于治疗原发性膜性肾病（pMN）等多种原发性肾小球疾病。其在原发性膜性肾病1b/2a期研究中展现出起效快、缓解持续、耐受性好、口服便捷等综合优势，有望为全球患者带来更优治疗选择。耐赋康®作为首个且唯一在中国、美国和欧洲获得完全批准的IgA肾病对因治疗药物，自纳入中国国家医保目录以来快速放量，已惠及超过两万名患者。公司亦正加快推进Gd-IgA1诊断试剂的转化，致力打造覆盖诊断、治疗、长期管理的一体化IgA肾病疾病管理生态。伊曲莫德（维适平®）在中国大陆的新药上市申请也已获受理，预计2025年底至2026年初获批，其新药上市申请也已获韩国受理。伊曲莫德已相继在中国澳门，新加坡和中国香港获批，并被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录（2024年），已在大湾区先行使用惠及溃疡性结肠炎患者，成为云顶新耀第三款商业化新药。2025年3月，云顶新耀启动了伊曲莫德位于嘉善工厂的生产建设项目，为伊曲莫德的本地化生产提供支持。云顶新耀正加快推进多个核心管线及技术平台的战略布局，进一步巩固其在亚洲领先创新药企中的市场地位。关于云顶新耀云顶新耀是一家专注于创新药和疫苗研发、临床开发、制造和商业化的生物制药公司，致力于满足亚洲市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业从事过高质量研发、临床开发、药政事务、化学制造与控制（CMC）、业务发展和商业化运营，拥有深厚的专长和丰富的经验。云顶新耀已打造多款疾病首创或者同类最佳的药物组合，公司的治疗领域包括肾科疾病、感染性和传染性疾病、自身免疫性疾病。有关更多信息，请访问公司网站：www.everestmedicines.com。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述，乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期，可能会使用"将"、"预期"、"预测"、"期望"、"打算"、"计划"、"相信"、"预估"、"确信"及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证，会受到风险、不确定性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务，除非法律要求。 Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年7月25日 - (亚太商讯 via SeaPRwire.com) - 随着粤港澳大湾区建设不断深化，区域内居民对跨境医疗服务与医疗保险协同发展的需求日益迫切。7月24日，一场以"粤港澳大湾区医疗保险发展"为主题的行业论坛于香港举行，来自保险、医疗、科技等领域的机构代表与专家齐聚一堂，围绕跨境医疗保障一体化、保险产品创新与服务标准化等核心议题展开深入交流。论坛期间，各方共同探讨大湾区医疗保险发展新路径，并见证跨境医疗行业解决方案正式发布。聚焦医疗互联互通，发布跨境保障方案论坛上，镁信健康创始人兼首席执行官张小栋先生指出，粤港澳大湾区作为我国经济最具活力的区域之一，在国家发展大局中具有重要战略地位。"塑造健康湾区"战略的践行，是对千万湾区居民"病有所医、医有所保"期盼的回应。镁信健康围绕"药品可及、医疗连接、支付简化"三个核心痛点，推出跨境医疗解决方案，具体涵盖：第一件事，是"把药带进来"。依托镁信创新药械的资源优势，致力于把最新上市的癌症、罕见病治疗药、以及海南特药特械等全球创新药械带到大湾区患者的身边；第二件事，是"把医连起来"。提供包括专家预约、陪诊、第二诊疗意见、住院手术安排等全流程服务，优化港人北上诊疗体验；第三件事，是"把支付变简单"。依托镁信的一码直付平台，探索实现患者北上就医无需垫付，努力让跨境医疗的保险理赔像扫码一样简单。镁信健康创始人兼首席执行官 张小栋在跨境医疗解决方案环节，中再寿险产品开发部总经理王明彦先生与镁信健康首席商务官郎立良先生也分别发表主题演讲。他们深入探讨了跨境医疗在大湾区面临的机遇与挑战，分享了在产品设计、服务模式等方面的创新实践与经验。汇聚行业智慧 共建健康湾区活动现场同步举行「服务国家战略，共建健康湾区」发布仪式，宣布各方将在资源整合，模式创新等层面持续合作，探索更多适配于大湾区的医疗保险产品与服务。在随后的圆桌论坛环节，由镁信健康首席商务官郎立良先生担任主持人，与尚志医疗集团医务行政总监、外科专科医生郭宝贤先生，中国太平洋人寿（香港）联席行政总裁、香港精算学会（ASHK）前主席、现任理事Simon Lam先生，香港精算视觉保险学会会长、大湾区保险学院联合创始人牟剑群先生，以及诺华香港的相关代表深入探讨大湾区医疗保融合的各方实践。各位嘉宾从不同角度分享了对大湾区医疗保险发展的见解与建议，探讨了如何加强大湾区医疗保障合作、提升医疗服务水平、促进保险产品创新等关键问题。镁信健康在论坛中积极发声，提出通过公立+特需/私立结合、资源整合等方式，赋能医疗资源的互补和互通，推动大湾区医疗保险服务的升级与优化，为大湾区居民提供更加优质的医疗保障体验，得到了与会嘉宾的广泛认可与支持。「服务国家战略，共建健康湾区」发布仪式凝聚信心 携手同行论坛压轴环节，中国太平洋人寿保险原董事长、大家保险集团原总经理徐敬惠先生发表主旨发言。他从行业发展的宏观角度，对大湾区医疗保险的未来发展进行了深入分析与展望，总结出三个"心"的感受。首先是信心，近年来，在各项政策的推动下，大湾区医疗互联互通成效明显，多项跨境医疗福利成功"过河"，跨境医疗的"民生流量"也在政策协同的推动下持续升温，这让我们对未来充满信心。第二个是"初心"，徐敬惠先生强调，"以人民健康为中心"的初心，是破解难题的指南针。最后是"同心"，不管是中再、镁信，还是医疗、医药机构，都在各自领域搭建着连通桥，各方携手共同推动大湾区医疗保险事业的发展，为大湾区居民的健康保驾护航。此次论坛发布的"湾区跨境医疗解决方案"，镁信健康深度参与并提供特药支持。它打破了地域壁垒，整合了两地资源，为跨境医疗服务的标准化、一体化树立了典范。这种合作模式不仅提升了居民的健康保障体验，也为行业探索出了一条可持续发展的新路。本次粤港澳大湾区医疗保险发展论坛的顺利举行，不仅推动了湾区保险行业对跨境医疗议题的深度关注，也为后续创新与产业协作奠定了良好基础。镁信健康作爲参与方之一，将持续深耕大湾区，携手更多伙伴推进医疗保障数智化转型，助力实现健康湾区的美好愿景。 Copyright 2025 亚太商讯 via SeaPRwire.com.

Starter Deck 03 ‘Ω to the Future’ marks the highly anticipated debut of Ultraman Omega in card form, featuring exclusive cards and brand new strategies that bring the latest TV series to life and allowing fans to experience the title hero’s journey.Booster Pack 04 ‘Gleam of Eternal Hope’ introduces powerful new versions of iconic Ultra Heroes including Ultraman Dyna, Z, and Trigger. These upgraded cards unlock expanded tactical possibilities, reshaping the game and delivering fresh competitive angles for seasoned players.With the release of both new sets as well as the return of fan-favourite ExP (Extra Parallel) rarity cards, and momentum building toward the Ultra League World Championship 2026, the Ultraman Card Game is poised to grow its global fanbase and strengthen its presence within the trading card game community.KUALA LUMPUR, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Tsuburaya Productions unveils today the latest additions to the ever-popular Ultraman Card Game - Starter Deck 03 ‘Ω to the Future’ and Booster Pack 04 ‘Gleam of Eternal Hope’, launching globally on Friday, 25 July 2025 and Friday, 1 August 2025 respectively. These upcoming game sets build on the momentum of the newly launched Ultraman Omega television series, as well as beloved characters such as Ultraman Arc, whilst introducing brand-new gameplay mechanics, evolution strategies and dynamic synergies centred around these iconic Ultra Heroes. Ultraman Omega Makes His First-Ever Card Game AppearanceA highlight of the new Starter Deck 03 ‘Ω to the Future’ is the much-anticipated debut of Ultraman Omega in card form. This new deck draws inspiration from the ongoing Ultraman Omega television series, which premiered in Japan earlier this month.Reflecting the show’s narrative, the deck features exclusive cards from the Ultraman Omega series, including the titular Ultraman Omega, Meteokaiju, and fan-favourite Giants of Light such as Ultraman Arc. These new cards introduce fresh gameplay mechanics that reward strategic thinking and foresight, from granting power boosts when fielding characters of the same type to enabling tactical card rotations that encourage smarter deck management. With these new mechanics and play styles, players can look forward to reliving key story moments and experiencing Ultraman Omega’s growth firsthand.As an added early-release bonus, players will also be able to receive a bonus pack of Booster Pack 04 ‘Gleam of Eternal Hope’ for every purchase of Starter Deck 03 ‘Ω to the Future’, offering fans an early taste of the upcoming expansion and even more ways to power up their decks.Fan-Favourite Heroes Return with Upgraded PowersBooster Pack 04 ‘Gleam of Eternal Hope’ continues to expand the strategic possibilities of the game, featuring powerful upgraded cards for popular Ultra Heroes including Ultraman Dyna, Ultraman Z, and Ultraman Trigger.These upgrades introduce new abilities that not only refresh existing decks but also deepen tactical options across competitive formats. With a more extensive card pool, players can look forward to more creative deckbuilding strategies that are sure to influence the current approach to gameplay.Collectors Rejoice: ExP (Extra Parallel) Cards Make a ReturnBack by popular demand, the ExP (Extra Parallel) rarity cards - first introduced in Booster Pack 02 ‘Vortex of Crimson and Azure’ - make a dazzling return in ‘Gleam of Eternal Hope’.These collector-favourite cards are known for their exclusive full-art illustrations, premium foil finish, and elegant gold framing. Scheduled to be revealed on Friday, 1 August 2025, ‘Gleam of Eternal Hope’ will see the addition of two brand-new types of ExP card, offering high visual appeal and collectability for long-time fans and new enthusiasts alike.Exclusive Box Topper: Alien Baltan The Space NinjaAdding to the excitement, each 24-pack box of ‘Gleam of Eternal Hope’ will include a special box topper card featuring Alien Baltan, one of the most iconic villains in Ultraman history.This unique card mirrors Baltan’s illusory powers, allowing an unlimited number of copies to be included in a single deck - a rare and rule-breaking mechanic. The artwork captures the classic scene of Baltan duplicating itself and unleashing its signature red freezing ray, leveraging nostalgia for long-term fans.Fans in Malaysia can look forward to purchasing the English-language Starter Deck 03 ‘Ω to the Future’ at MYR 46.00 and Booster Pack 04 ‘Gleam of Eternal Hope’ in either individual packs at MYR 18.00 or as a 24-pack box at MYR 432.00 at authorised hobby stores, major retailers, and online platforms.These releases are poised to equip both new and veteran Ultra Leaguers with competitive decks ahead of major events, including the upcoming inaugural Ultra League World Championship 2026, set to take place on 9 and 10 May 2026 in Tokyo, Japan. This prestigious tournament will see players from around the world battling through regional qualifiers for a shot at the title of world’s best Ultra Leaguer, with exclusive cards and gameplay accessories up for grabs. For more information on the Ultraman Card Game, please refer to https://ultraman-cardgame.com/page/my/top.About Tsuburaya ProductionsTsuburaya Productions is a global entertainment company providing content, products and services full of creativity and innovation. Since the airing of Ultra Q and Ultraman in 1966, the company has continued to create characters and stories that are loved by fans worldwide.TSUBURAYA PRODUCTIONS Official Global Site: https://tsuburaya-prod.com/Ultraman Card Game Official Website: https://ultraman-cardgame.com/About Ultraman Card GameThe Ultraman Card Game is a dynamic trading card game developed by Tsuburaya Productions, bringing the iconic Ultraman universe to life through strategic gameplay and collectible cards. Designed for fans of all ages, the game features high-quality artwork showcasing Ultraman's heroes, kaiju, and special moves, offering both engaging play and collectibility. With simultaneous releases in multiple languages across various regions, the Ultraman Card Game invites players around the world to explore the rich legacy of Ultraman, engage in epic battles, and grow their collections. Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the “Sellers”), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue.Everest Medicines, together with its controlling shareholder CBC Group and the placing agents, entered into a placing and subscription agreement for the sale of 22,561,000 shares at a purchase price of HK$69.70 per share, representing:- a discount of approximately 10.12% to the closing price of HK$77.55 per share on July 24, 2025.- a discount of approximately 4.98% to the average closing price of HK$73.35 per Share as quoted on the Stock Exchange for the five consecutive trading days immediately prior to and including the Last Trading Date.- a premium of 16.15% to the volume weighted average price of HK$60.01 per Share as quoted on the Stock Exchange for the thirty consecutive trading days immediately prior to the Last Trading Date and including the Last Trading Date.The gross proceeds from the Placing and Subscription are expected to be approximately HK$1,572.50 million, and the net proceeds (after deducting all related expenses, including commission and levies) will be approximately HK$1,553.39 million.Everest Medicines intends to use approximately 50% of the net proceeds (approximately HK$776.69 million) to support global research and development of pipeline products, approximately 40% (approximately HK$621.36 million) to commercialization efforts including the launch of new products, and 10% (approximately HK$155.34 million) to working capital and general corporate purposes.“This placement was well-received by several leading international long-only funds and was significantly oversubscribed, reflecting strong capital market confidence in Everest’s commercial execution capabilities and innovative R&D strengths,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “It also underscores investors’ endorsement of our long-term strategic vision. We will use the proceeds to accelerate the development of innovative pipelines and our proprietary AI+mRNA platform, while advancing the commercialization of our existing portfolio. With a strengthened capital base, we are poised to drive both commercialization and innovation, delivering greater value to patients and shareholders.”Everest has built an industry-leading, fully integrated, and localized AI+mRNA platform, enabling the development of multiple oncology and autoimmune disease programs, including EVM14, an off-the-shelf therapeutic mRNA cancer vaccine; EVM16, a personalized mRNA cancer vaccine; and an in vivo CAR-T program aimed at building a differentiated portfolio of precision immunotherapies.- The first patient has been dosed with Everest’s internally developed personalized mRNA cancer vaccine (PCV) EVM16 at Peking University Cancer Hospital in the investigator-initiated clinical trial (IIT). Early results showed strong immunogenicity and specific T-cell responses even at a low starting dose in advanced cancer patients.- The Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) vaccine, has been accepted by both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA), making it Everest's first mRNA cancer therapeutic vaccine to achieve dual IND submissions in both China and the United States. The first clinical batch of EVM14 was successfully released from Everest’s Jiashan manufacturing site on June 9, and is anticipated to be delivered to U.S. clinical centers by mid-August. This batch will support the clinical trials of EVM14 in both China and the United States (US).- Everest’s in vivo CAR-T program is founded upon its proprietary targeted LNP (tLNP) delivery system and has shown promising results in both humanized mouse models and non-human primates. It offers key advantages including off-the-shelf availability, lymphodepletion-free administration, and dose controllability.EVER001, a next-generation covalent reversible BTK inhibitor with global rights, is advancing through global multi-center clinical studies for glomerular diseases such as primary membranous nephropathy (pMN). Positive results from its Phase 1b/2a clinical trial demonstrated rapid onset, durable response, good tolerability, and oral convenience, offering strong potential to address unmet needs in renal disease treatment worldwide.NEFECON®, the first and only etiological treatment for IgA nephropathy (IgAN) full approved in China, the U.S., and Europe, continues to gain strong commercial traction in China following its inclusion in the National Reimbursement Drug List (NRDL), benefiting over 20,000 patients to date. Everest is also accelerating the development of its proprietary diagnostic test for Gd-IgA1 to build an integrated disease management ecosystem encompassing diagnosis, treatment, and long-term care.The New Drug Application (NDA) for Etrasimod (VELSIPITY®) has been accepted in Mainland China, with approval anticipated between late 2025 and early 2026. The NDA has also been accepted in South Korea. VELSIPITY® has been commercially launched in Macao SAR, Singapore and Hong Kong SAR in 2024. As Everest’s third commercialized product, VELSIPITY® has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. In March 2025, Everest has launched the construction project at its Jiashan manufacturing site to support the local production for VELSIPITY®.Everest Medicines is accelerating the strategic advancement of its core pipeline and AI+mRNA technology platforms to further solidify its position as a leading innovative biopharmaceutical company in Asia.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年7月24日 - (亚太商讯 via SeaPRwire.com) - 日本东京证券交易所挂牌企业 Quantum Solutions Co.,Ltd.（2338.T）于7月23日宣布，正式启动比特币储备业务，计划在未来12个月内逐步建立最多3,000枚比特币（BTC）的储备仓位，作为其长期财务战略中的数字资产配置项目。该计划将由集团全资拥有的香港子公司 GPT Pals Studio Limited 负责执行，初期建设所需的资金已获国际私募投资机构 Integrated Asset Management (Asia) Limited 提供，金额为1,000万美元。这是Quantum Solutions首次在公开层面披露其对加密资产的部署计划。公告显示，该公司将比特币视为未来企业资产结构中的长线"战略型储备品种"， 计划将分阶段实施，以确保其得到适当风险管控和财务管治。3,000枚比特币（BTC）计划将采取阶段化路径实施，购入时机和规模取决于现行市场条件、资本可用性和监管环境。Integrated Asset Management (Asia)是一家总部位于香港的投资公司，于 2014 年主导了对福布斯传媒的收购。该公司由任德章先生创立，专注于公募和私募股权投资。任先生透过其控股公司，包括Integrated Asset Management (Asia) 持有福布斯传媒的多数股权，余下少数股权则由福布斯家族持有。Integrated Asset Management (Asia)参与这项计画突显了机构投资者对将比特币纳入现代企业的财务考量之开放程度日益提高。根据披露，该比特币储备项目将由GPT Pals Studio Limited具体承担相关建设与运维工作，公司已开始建立安全且可审计的数位资产基础设施,包括专属数字资产冷热钱包隔离系统、内部风险控制和会计机制，等基础工作。公司的董事会及审计委员会将根据适用的监管和会计标准，定期监督投资组合的估值、风险敞口和管治。根据当前市场价格测算，3,000枚比特币的总价值约为538亿日元（折合约25亿港元），公司表示，这是一项长期的投资策略，而非短期投机，并表示其资产配置将以财务稳定性与股东价值为导向。Quantum Solutions 执行长（Francis Zhou）表示："我们具备独特优势，可打造以比特币为核心的资本架构。我们的目标不仅是累积比特币，更要以机构级的纪律执行此目标。""我们正与顶尖的资产管理公司、主权财富管理机构以及金融科技领袖进行高层次的磋商，以负责且迅速的方式扩展我们的财务规划蓝图。"当前，全球愈来愈多国际上市企业与大型机构投资者已将比特币纳入财务结构之中，用以对冲通胀及分散货币政策风险。Quantum Solutions 此次计划的推出，正处于该趋势的早期阶段。公司本次选择以香港作为数字资产业务的运营中心，也反映出其对区域金融制度、基础设施与监管环境的信心。Integrated Asset Management Limited创办人任德章表示："Quantum Solutions 展现出明确的策略愿景与坚定的决心。我认为他们在打造具规模的比特币财库方面有潜力引人注目，我期待支持他们在开拓机构通道及资本协调的努力。对于具备- 全球拓展雄心与专注执行力的企业而言，这是一个恰逢其时的良机。"该计划的启动，亦可视为Quantum Solutions从传统科技解决方案企业向多元化财务体系构建方向迈出的关键一步。配合未来业务增长，公司将在资本结构层面持续评估新型资产工具与技术平台的整合可能性，以提升综合财务稳健性与全球应对能力。据悉，若本次比特币储备业务在未来对财务报表构成实质性影响，公司将依据东京交易所相关规定进行必要的信息披露与更新。关于 Quantum SolutionsQuantum Solutions Co.,Ltd.（东京证券交易所：2338.T）是一家总部位于日本东京的高成长科技企业，专注于人工智能、大数据分析及区块链相关技术的研发与应用。公司成立于2004年，并于东京证券交易所挂牌上市。Quantum Solutions 的核心业务涵盖金融科技、医疗健康、智能制造等多个行业领域，致力于以技术驱动产业转型。截至2025年2月28日，公司实现收入约470 万美元，拥有数项游戏类别的注册商标和技术专利。更多信息请访问公司官网：https://www.quantum-s.co.jp/en/corporate前瞻性声明本新闻稿包含根据公司目前可取得之资讯，以及对未来事件与预期所作的若干假设所形成的前瞻性声明。此类声明涉及各种风险与不确定性，包括但不限于政策变动、市场状况、技术发展及监管因素，皆可能导致实际结果与此类声明中所表达或暗示的结果出现重大差异。建议现有及潜在投资者审慎评估潜在风险，并避免对本新闻稿中所包含的任何前瞻性声明寄予过高信赖。此类声明仅适用于本新闻稿发布之日，除法律另有规定外，公司并无义务因新资讯、未来事件或其他情况而更新或修正任何前瞻性声明。如有进一步查询，请联络：香港/国际：Mr. Steven TungEmail: steven.tung@quantum-s.co.jp日本：Ms. Linda PengEmail: linda.peng@quantum-s.co.jp Copyright 2025 亚太商讯 via SeaPRwire.com.